文献速递哮喘呼吸道感染

抗IL-5治疗对轻度哮喘鼻病毒诱导的巨噬细胞、B细胞和中性粒细胞反应的影响(MATERIAL):一项安慰剂对照双盲研究

Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

该安慰剂对照双盲试验纳入未用激素的轻度哮喘患者,随机后静脉给予750 mg美泊利单抗,2周后以鼻病毒16型攻击,评估FEV1、FVC、呼出气一氧化氮、症状评分、病毒载量及血液、BALF和痰中免疫参数。美泊利单抗降低基线血嗜酸性粒细胞及其活化,趋势性降低痰嗜酸性粒细胞,增强循环NK细胞,但不影响FEV1、FVC和呼出气一氧化氮;鼻病毒攻击后未阻止嗜酸性粒细胞活化,但增强局部B淋巴细胞和巨噬细胞、减少中性粒细胞及其活化,并增强分泌型IgA、降低BALF中类胰蛋白酶。结论认为美泊利单抗未能阻止残留嗜酸性粒细胞活化,但改变了鼻病毒16型诱导的免疫反应,后者可能由嗜酸性粒细胞减少所致,不能排除嗜碱性粒细胞的作用。

要点

  • 美泊利单抗降低轻度哮喘基线血嗜酸性粒细胞及活化,趋势性降低痰嗜酸性粒细胞。
  • 美泊利单抗不影响FEV1、FVC和呼出气一氧化氮,鼻病毒攻击后亦无影响。
  • 鼻病毒攻击后美泊利单抗增强BALF中B淋巴细胞和巨噬细胞、减少中性粒细胞及其活化。

核心结论

  • 美泊利单抗未能阻止轻度哮喘患者残留嗜酸性粒细胞的活化,但改变了鼻病毒16型诱导的免疫反应。
  • 上述免疫效应可能由嗜酸性粒细胞数量减少所致,但不能排除嗜碱性粒细胞的作用。

研究设计与样本

  • 安慰剂对照双盲试验,纳入未用激素的轻度哮喘患者,按嗜酸性粒细胞数量随机。
  • 患者静脉给予750 mg美泊利单抗,2周后以鼻病毒16型攻击。
  • 评估FEV1、FVC、呼出气一氧化氮、症状评分(哮喘控制评分)、病毒载量(PCR)、嗜酸性粒细胞数量及血液、BALF和痰中体液与细胞免疫参数。
  • 试验注册于www.clinicaltrials.gov(NCT 01520051)。

主要发现

  • 美泊利单抗降低基线血嗜酸性粒细胞及其活化,趋势性降低痰嗜酸性粒细胞,增强循环自然杀伤细胞。
  • 美泊利单抗在基线及鼻病毒16型攻击后均不影响FEV1、FVC和呼出气一氧化氮。
  • 鼻病毒16型攻击后,美泊利单抗未阻止嗜酸性粒细胞活化,但增强局部B淋巴细胞和巨噬细胞,减少中性粒细胞及其活化。
  • 美泊利单抗增强BALF中分泌型IgA并降低类胰蛋白酶。
  • 美泊利单抗特别影响鼻病毒16型诱导的BALF中巨噬细胞炎性蛋白-3a、血管内皮生长因子-A和IL-1RA产生。

临床怎么用

  • 在轻度哮喘中,美泊利单抗虽降低血嗜酸性粒细胞,但未改善肺功能或呼出气一氧化氮,不支持其用于该人群的常规治疗。
  • 美泊利单抗改变鼻病毒诱导的局部免疫反应,提示抗IL-5治疗可能影响呼吸道病毒感染后的免疫应答,需进一步研究。

局限性

  • 不能排除嗜碱性粒细胞在观察到的免疫效应中的作用。
  • 研究为单次鼻病毒16型攻击模型,结果外推至自然感染需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma, and therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 and efficiently attenuates eosinophils, proved clinically effective in severe eosinophilic asthma but not in mild asthma. OBJECTIVES: To study the effect of mepolizumab on virus-induced immune responses in mild asthma. METHODS: Patients with mild asthma, steroid-naive and randomized for eosinophil numbers, received 750 mg mepolizumab intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were challenged with rhinovirus (RV) 16. FEV1, FVC, fractional exhaled nitric oxide, symptom scores (asthma control score), viral load (PCR), eosinophil numbers, humoral (luminex, ELISA), and cellular (flow cytometry) immune parameters in blood, BAL fluid, and sputum, before and after mepolizumab and RV16, were assessed. MEASUREMENTS AND MAIN RESULTS: Mepolizumab attenuated baseline blood eosinophils and their activation, attenuated trendwise sputum eosinophils, and enhanced circulating natural killer cells. Mepolizumab did not affect FEV1, FVC, and fractional exhaled nitric oxide, neither at baseline nor after RV16. On RV16 challenge mepolizumab did not prevent eosinophil activation but did enhance local B lymphocytes and macrophages and reduce neutrophils and their activation. Mepolizumab also enhanced secretory IgA and reduced tryptase in BAL fluid. Finally, mepolizumab affected particularly RV16-induced macrophage inflammatory protein-3a, vascular endothelial growth factor-A, and IL-1RA production in BAL fluid. CONCLUSIONS: Mepolizumab failed to prevent activation of remaining eosinophils and changed RV16-induced immune responses in mild asthma. Although these latter effects likely are caused by attenuated eosinophil numbers, we cannot exclude a role for basophils. Clinical trial registered with www.clinicaltrials.gov (NCT 01520051).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Sabogal Piñeros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study. Am J Respir Crit Care Med. 2019. PMID: 30192638. doi:10.1164/rccm.201803-0461OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。